Efficacy of gastrointestinal medications in patients with upper gastrointestinal symptoms -randomized, parallel group, open-label study- - Efficacy of gastrointestinal medications in patients with upper gastrointestinal symptoms

Japan Dyspepsia Society0 个研究点目标入组 500 人开始时间: 2011年4月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients who have alarm symptoms, such as vomiting, gastrointestinal bleeding or acute weight loss requiring endoscopy. (2) Patients who are judged by the investigator to require a prompt endoscopy. (3) Patients who have a confirmed or suspected malignant lesion. (4) Patients who have prior gastrointestinal resection or vagotomy. (5) Patients with irritable bowel syndrome. (6) PPIs, H2-receptor antagonists, prokinetic agents, gastric mucosal protective agents, anticholinergics, antidepressants, anxiolytics, steroids (other than topical steroids), non-steroidal anti-inflammatory drugs, aspirin or bisphosphonates were discontinued at least 1 week before study entry and were not allowed during the study period. (7) Patients who are judged to be ineligible for study entry due to serious hepatic, renal, or cardiac disease. (8) Patients who might possibly be pregnant or were lactating. (9) Patients who are judged to be ineligible for study entry by the investigator.

发起方

Japan Dyspepsia Society